The warning follows a patient complaint Aug. 14 about black particulate matter found in a vial of semaglutide, according to a Nov. 1 news release from the agency. Subsequent inspections by California regulatory authorities revealed deficiencies at Fullerton Wellness, prompting the facility to voluntarily cease operations Sept. 23.
A follow-up inspection Oct. 17 uncovered practices that could lead to drug contamination, including the use of non-sterile ingredients without proper sterilization.
The agency urged healthcare professionals to check their supplies, quarantine any drugs from Fullerton Wellness and avoid administering them. Patients who have received the compounded drugs were advised to stop using them and consult healthcare providers.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.